13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nanotechnological carriers for cancer chemotherapy: the state of the art.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cancer is a term used for a heterogeneous group of malignant diseases in which abnormal cells divide without control and are able to invade other tissues, resulting in metastasis. According to the last data of World Health Organization the incidence and mortality rates of cancer are high and tend to increase. Chemotherapy is usually used in cancer treatments, but due to the lack of specificity of drugs, is associated to various and damaging side effects that have a severe impact on patients quality of life. Nanotechnology is actually an important area of interest in science and technology, which has been extensively explored during the last decade, particularly in the development of carriers for cytotoxic drugs. These carriers include vesicular and particulate systems such as liposomes, niosomes, transfersomes, ethosomes, micelles, dendrimers, and polymeric, protein and lipid nanoparticles. Polymer-drug conjugates and antibody-drug conjugates have also been studied. The present review is an attempt to contemplate the studied nanocarriers in the field of anticancer drugs delivery, their advantages and disadvantages and future perspectives.

          Related collections

          Author and article information

          Journal
          Colloids Surf B Biointerfaces
          Colloids and surfaces. B, Biointerfaces
          1873-4367
          0927-7765
          Feb 1 2015
          : 126
          Affiliations
          [1 ] Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, N.° 228, 4050-313 Porto, Portugal(1). Electronic address: msrestanqueiro@ff.up.pt.
          [2 ] Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, N.° 228, 4050-313 Porto, Portugal(1). Electronic address: hamaral@ff.up.pt.
          [3 ] Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, N.° 228, 4050-313 Porto, Portugal(1). Electronic address: jmgmconceicao@ff.up.pt.
          [4 ] Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, N.° 228, 4050-313 Porto, Portugal(1). Electronic address: slobo@ff.up.pt.
          Article
          S0927-7765(14)00728-0
          10.1016/j.colsurfb.2014.12.041
          25591851
          345245f5-06c6-40c3-9731-595adb46826b
          Copyright © 2014 Elsevier B.V. All rights reserved.
          History

          Anticancer drugs,Cancer,Dendrimers,Liposomes,Micelles,Nanoparticles

          Comments

          Comment on this article